Cas9 nickase shrinks CAG repeats and eases symptoms in Huntington's mice
Start here
Researchers report that a Cas9 nickase approach can contract the expanded CAG/CTG repeats that drive Huntington's disease, and that this contraction is associated with phenotypic improvements in a mouse model of the disorder. The work, published in Science Translational Medicine on October 21, 2026 (Volume 18, Issue 872), points to a gene-editing strategy aimed at the root mutation rather than its downstream effects. Details such as sample size, specific effect sizes, and the durability of the improvements have not been disclosed in the material available so far. Questions also remain open about delivery, off-target editing, and how the mouse findings would translate to patients before any clinical testing could be considered.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- ScienceCas9 nickase–mediated contraction of CAG/CTG repeats is associated with phenotypic improvements in a Huntington’s disease mouse model
Cas9 nickase–mediated contraction of CAG/CTG repeats is associated with phenotypic improvements in a Huntington's disease mouse model. The article appears in Science Translational Medicine, Volume 18, Issue 872 (October 2026); the current material does not provide the full text, sample size, or specific effect sizes.
Coverage and heat for this story
Reports so far 1·Heat now 7·Peak heat 10 (Oct 21 15:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.